Answers are grounded in this paper and cite their sources.
We present the clinical course of a 4-year-old girl with neurofibromatosis type 1-associated, unresectable, symptomatic urinary bladder ganglioneuroma. She was initially trialed on sirolimus without response and subsequently responded to MEK inhibitor trametinib, with improvement clinically and radiographically over 10 months. This report broadens the repertoire of therapeutic strategies for MEK inhibition in diseases related to the MAPK pathway.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: